Shannon Duffy

Shannon Duffy asked about the current refill rates for VYKAT XR, especially with a larger proportion of patients on the drug for several months, and how the average weight of new patients might change over time, particularly with an increase in older patients.

Answer

Anish Bhatnagar, Chairman and CEO, explained that the average weight of new patients is likely higher than in clinical trials, with more older patients (27-45 years) coming on therapy, suggesting a gentle increase in average weight over time. Meredith Manning, Chief Commercial Officer, expressed satisfaction with high adherence and refill rates as patients settle into optimal doses.

Shannon Duffy asked about the refill rates observed for VYKAT XR, particularly as a larger proportion of patients have been on the drug for several months, and how the average weight of new patients is expected to change over time, especially with more older patients.

Answer

Anish Bhatnagar, Chairman and CEO, stated that the average weight of new patients is likely higher than in clinical trials, with more older patients coming on, suggesting a gentle increase in average weight over time. Meredith Manning, Chief Commercial Officer, expressed satisfaction with high adherence rates and patients staying on therapy as they settle into optimal doses.